 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
ALK Mutation Testing for NSCLC on the Rise among Oncologists, BioTrends Survey Finds
April 18, 2012
ALK Mutation Testing for NSCLC on the Rise among Oncologists, BioTrends Survey Finds
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Patient Enrichment to Limit PGx Testing for NSCLC Could Lower Costs, but Miss Responders
March 21, 2012 / Pharmacogenomics Reporter - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter - Pfizer and Collaborators Developing Next-Gen Sequencing Test for Crizotinib Resistance Mutations
March 27, 2013 / Pharmacogenomics Reporter - Pfizer, Collaborators Developing NanoString ALK Test as Lower-Cost Alternative to FISH, IHC
December 19, 2012 / Pharmacogenomics Reporter - Early Data Convinces Some Oncologists to Treat ROS1-Positive NSCLC Patients with Xalkori
June 6, 2012 / Pharmacogenomics Reporter